Skip to content
Thursday 20 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,721.46
-0.20%
DAX
25,965.91
-0.48%
CAC 40
8,463.54
-0.45%
STOXX 50
6,424.40
-0.31%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Tuesday 04 January 2022 7:42 am

Boost white blood cells in immune system as they are able to fight off Omicron variant, Covid scientists find

By: Michiel Willems

Add as a preferred source on Google
PCR-TEST-KIT-FIRM
A student taking a PCR test

The immune system’s white blood cells are able to mount an immune response against the Omicron variant of Covid-19, according to a new study.

Due to Omicron having a higher number of mutations than other Covid variants, it can sometimes slip past the antibodies created by vaccination or infection.

However, if the virus still does enter the body, the white blood cells, known as T-cells, will attack.

The new research, from the University of Melbourne and Hong Kong University of Science and Technology (HKUST), involved investigators analysing over 1,500 fragments of SARS-CoV-2’s viral proteins – called epitopes – that have been found to be recognised by T-cells in recovered Covid-19 patients or after vaccination.

The team’s findings, published in the peer-reviewed journal Viruses, suggest Omicron is unlikely to be able to evade T-cells, adding to a growing body of evidence from research groups around the world who are also investigating T-cell responses to Covid-19.

University of Melbourne professor and co-leader of the research, Matthew McKay, said: “Despite being a preliminary study, we believe this is positive news.

“Even if Omicron, or some other variant for that matter, can potentially escape antibodies, a robust T-cell response can still be expected to offer protection and help to prevent significant illness.

“Based on our data, we anticipate that T-cell responses elicited by vaccines and boosters, for example, will continue to help protect against Omicron, as observed for other variants. We believe this presents some positive news in the global fight against Omicron.”

According to the researchers, the most concerning aspect of Omicron is the abundance of mutations in its spike protein, which is the primary target of Covid-19 vaccines. The spike enables the virus to attach and enter cells in humans.

Current vaccines induce neutralising antibodies aimed at blocking this process, however these antibodies have been reported to be less effective against Omicron compared with previous variants.

In analysing virus epitopes from the spike protein that are targeted by T-cells in vaccinated or previously infected individuals, the study found that only 20% showed mutations associated with Omicron.

Even then, these mutations do not necessarily mean the virus will be able to evade the body’s T-cells, researchers said.

Read more

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business
  • Media

Related Topics

  • Pharmaceuticals
  • Pharmaceuticals

Trending Articles

  • Jobless Banquet: Youth unemployment surge ‘sends Neets to KFC’

  • City law firm sues prominent Emirati business family

  • Amanda Blanc has worked her magic at Aviva

  • As it happened: Miners fuel FTSE 100 recovery; oil jumps as Trump claims Strait of Hormuz

  • House prices in wealthy London boroughs fall by up to £300,000

More from Morning Wire

  • Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

    Business Wire
  • Airspan Delivers Revenue Growth and Profitability in First Half 2026

    Business Wire
  • AT&T-Led Neutral-Host Network Powers New Connectivity Experience at Davis Wade Stadium

    Business Wire
  • Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

    Business Wire
  • Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026

    Business Wire
  • ReNew Announces Results for the First Quarter for Fiscal Year 2027 (Q1 FY27), Ended June 30, 2026

    Business Wire
  • Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

    Business Wire
  • ‘Alice in Wonderland’ workspace firm lands £129m Aberdeen-backed finance

    Property
    Modern reception area with unique legs art installation, white desk, and colorful stools.
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook